Subscribe now

Comment and Health

Should NHS limit spending on treatments for rare diseases?

As pressures on the National Health Service grow, should costly new treatments for rare diseases get a tougher ride, wonders Zara Aziz

By Zara Aziz

25 January 2017

NHS sign

Dan Kitwood/Getty

THE vast majority of people in the UK support National Health Service treatments for rare diseases. But would that still hold true if treatments for cancer or hip and knee surgery were to be rationed on a regular basis?

As the NHS winter crisis deepens, it would appear that with increasing longevity and complexity of medical conditions the economic burden on health and social care has no limit. So such questions arise.

It remains a challenge, even more so in the current climate, to balance finances with health benefits for the population. Can we as a society afford to…

Sign up to our weekly newsletter

Receive a weekly dose of discovery in your inbox! We'll also keep you up to date with New Scientist events and special offers.

Sign up

To continue reading, subscribe today with our introductory offers

View introductory offers

No commitment, cancel anytime*

Offer ends 2nd of July 2024.

*Cancel anytime within 14 days of payment to receive a refund on unserved issues.

Inclusive of applicable taxes (VAT)

or

Existing subscribers

Sign in to your account
or

Register for FREE to read this article in full

Register to access free content